Blue Jet Healthcare Ltd
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
- Market Cap ₹ 8,169 Cr.
- Current Price ₹ 470
- High / Low ₹ 1,028 / 325
- Stock P/E 33.0
- Book Value ₹ 78.4
- Dividend Yield 0.26 %
- ROCE 26.5 %
- ROE 19.9 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 24.0%
Cons
- Working capital days have increased from 158 days to 224 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 538 | 499 | 683 | 721 | 712 | 1,030 | 947 | |
| 325 | 292 | 434 | 502 | 481 | 652 | 653 | |
| Operating Profit | 214 | 207 | 249 | 219 | 231 | 378 | 294 |
| OPM % | 40% | 41% | 36% | 30% | 32% | 37% | 31% |
| 6 | 9 | 19 | 24 | 18 | 46 | 69 | |
| Interest | 7 | 5 | 3 | 1 | 0 | 0 | 6 |
| Depreciation | 18 | 20 | 22 | 25 | 28 | 18 | 24 |
| Profit before tax | 194 | 190 | 243 | 217 | 220 | 406 | 333 |
| Tax % | 25% | 26% | 25% | 26% | 26% | 25% | 25% |
| 145 | 142 | 182 | 160 | 164 | 305 | 248 | |
| EPS in Rs | 24,118.33 | 1,428.77 | 10.47 | 9.23 | 9.44 | 17.59 | 14.29 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 11% | 7% | 8% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 10% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 16% |
| TTM: | -17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 24% |
| Last Year: | 20% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.60 | 10 | 35 | 35 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 | 1,098 | 1,325 |
| 74 | 52 | 19 | 5 | 3 | 21 | 42 | |
| 92 | 142 | 173 | 176 | 211 | 263 | 239 | |
| Total Liabilities | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
| 107 | 139 | 156 | 151 | 172 | 300 | 316 | |
| CWIP | 2 | 3 | 3 | 30 | 147 | 89 | 301 |
| Investments | 26 | 37 | 94 | 189 | 250 | 187 | 252 |
| 229 | 355 | 460 | 491 | 489 | 841 | 771 | |
| Total Assets | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 122 | 137 | 146 | 142 | 241 | 46 | 334 | |
| -45 | -61 | -76 | -147 | -264 | -35 | -276 | |
| -72 | -21 | -56 | -4 | -2 | -19 | -31 | |
| Net Cash Flow | 5 | 55 | 14 | -10 | -24 | -8 | 28 |
| Free Cash Flow | 106 | 85 | 125 | 83 | 68 | -34 | 115 |
| CFO/OP | 80% | 66% | 70% | 92% | 109% | 36% | 151% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 | 91 | 124 | 131 |
| Inventory Days | 120 | 253 | 133 | 137 | 151 | 209 | 157 |
| Days Payable | 90 | 128 | 72 | 58 | 35 | 70 | 48 |
| Cash Conversion Cycle | 110 | 231 | 183 | 199 | 206 | 262 | 240 |
| Working Capital Days | 55 | 89 | 103 | 120 | 92 | 157 | 224 |
| ROCE % | 58% | 53% | 35% | 30% | 40% | 26% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Export Revenue Contribution % |
|
||||
| Fixed Asset Turnover Ratio x |
|||||
| Number of Customers Globally Number |
|||||
| Total Reaction Capacity KL |
|||||
| Capacity Utilization (Annualized) % |
|||||
| Commercialized Products - Contrast Media Intermediates Number |
|||||
| Commercialized Products - High Intensity Sweeteners Number |
|||||
| Commercialized Products - Pharma Intermediates & APIs Number |
|||||
| Number of Manufacturing Facilities Number |
|||||
| Total Commercialized Products Number |
|||||
| Global Market Share - Top 4 Contrast Media Players (served by Blue Jet) % |
|||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
3h - Blue Jet Healthcare filed FY2026 annual secretarial compliance report; no non-compliances or regulatory actions noted.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7h - Intimation of the Newspaper Publication for Extra Ordinary General Meeting to be held on 17th June, 2026
-
Notice Of Extra-Ordinary General Meeting Of Blue Jet Healthcare Limited
1d - EGM on June 17, 2026 to approve fund raising up to ₹10,000 million via equity and eligible securities.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 1d
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
2d - Audio recording of FY2026 results conference call held on May 25, 2026 uploaded online.
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptAI SummaryPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
Product Portfolio
A) Contrast Media Intermediates (67.7% of FY24 revenue)[1]
Contrast media are chemical agents that enhance imaging clarity for diagnostic purposes, making tissues more visible under X-rays, CT scans, MRIs, and ultrasounds. The company supplies critical starting and advanced intermediates to the world's top contrast media manufacturers.